Over a year ago, SITC launched the bold #SITCQuestfor100 – a mission to accelerate the approval of 100 novel immuno-oncology (IO) agents over the next decade. We are convinced that groundbreaking, clinically meaningful IO innovations are on the horizon, with the potential to transform outcomes for patients worldwide. SITC is proud to be at the forefront of this effort, leading critical conversations, convening the scientific community, hosting impactful events and publishing forward-thinking research to drive the field forward.
To this end, SITC recently hosted the
2025 NYSE Biotech Program, a sold-out event featuring forward-looking discussions with leading experts. Sessions explored the future of T-cell engagers, the impact of China’s clinical research landscape and strategic pathways for advancing novel immunotherapies. ZS also convened a dedicated panel and mixer focused on IO launch planning for biotech companies. This dynamic gathering brought together a diverse group of stakeholders for high-impact dialogue and strategic networking, all in pursuit of our shared goal to deliver 100 new IO agents by 2034.
In addition, SITC has published the latest manuscript in its
Next Wave of IO series. The latest installment highlights the most pressing challenges, and promising opportunities, for achieving high clinical impact across scientific, clinical, and regulatory arenas. Focusing on anti-tumor mechanisms, toxicity and resistance, these insights will be critical as we chart the course for the next decade of progress in IO.
With the 2025 Prescription Drug User Fee Act (PDUFA) dates on the horizon, we remain energized by the momentum of #SITCQuestfor100. I’m especially excited about the research and progress that will emerge from the 40th Anniversary Annual Meeting & Pre-Conference Programs (SITC 2025). I strongly encourage you to
register for SITC 2025 before Aug. 13 to take advantage of early registration rates. Additionally,
Late-Breaking Abstracts – Clinical Only (LBA) are being accepted through Sept. 15 at 5 p.m. PT. Don’t miss the opportunity to share your latest clinical findings!
Together, we are charting the course toward a new era of cancer treatment.
Join us as we continue our ambitious #SITCQuestfor100.
SITC honors the memory of Zelig Eshhar who passed away on July 3, 2025. Dr. Eshhar’s groundbreaking work in CAR T-cell therapy revolutionized the landscape of cancer treatment. SITC was privileged to recognize his pioneering contributions to immunotherapy by inducting him into the Academy of Immuno-Oncology (FAIO) in 2021. In 2022, he was honored with the Richard V. Smalley Memorial Award and Lectureship, which featured several individuals whose innovative work has made a profound and lasting impact on the field. We invite you to
view this special video tribute recognizing Dr. Eshhar’s trailblazing achievements.
Program Spotlight
SITC 2025 – Register by Aug. 13 for Discounted Rates!
CANCER IMMUNOTHERAPY WINTER SCHOOL
Registration Now Open for 2026 Cancer Immunotherapy Winter School,
Feb. 16–18
One of SITC’s most popular programs is now accepting registrations! The Cancer Immunotherapy Winter School offers in-depth exploration of the core principles of tumor immunology and cancer immunotherapy, along with the latest advances in the field.
Join program organizers Kristin Anderson, PhD – University of Virginia, Chrystal Paulos, PhD – Winship Cancer Institute at Emory University, Ryan J. Sullivan, MD – Harvard Medical School, Massachusetts General Hospital and program advisor Daniel J. Powell Jr., PhD – University of Pennsylvania for this essential educational event.
To support young investigators and clinicians interested in attending the Cancer Immunotherapy Winter School, SITC is accepting applications for
travel awards. Applications will be accepted through Aug. 18 at 5 p.m. PST.
Register before the New Year to save up to $250 off regular rates – secure your spot today!